MAIA Biotechnology, Inc. (MAIA)
1.15
+0.02
(+1.77%)
USD |
NYAM |
Oct 23, 16:00
1.145
0.00 (0.00%)
After-Hours: 20:00
MAIA Biotechnology Enterprise Value : 42.34M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 42.34M |
| October 22, 2026 | 41.13M |
| October 21, 2026 | 41.74M |
| October 20, 2026 | 40.52M |
| October 19, 2026 | 37.48M |
| October 16, 2026 | 39.30M |
| October 15, 2026 | 40.52M |
| October 14, 2026 | 40.52M |
| October 13, 2026 | 42.95M |
| October 12, 2026 | 44.17M |
| October 09, 2026 | 46.60M |
| October 08, 2026 | 42.34M |
| October 07, 2026 | 44.17M |
| October 06, 2026 | 44.78M |
| October 05, 2026 | 44.17M |
| October 02, 2026 | 44.78M |
| October 01, 2026 | 43.56M |
| September 30, 2026 | 44.17M |
| September 29, 2026 | 42.34M |
| September 28, 2026 | 44.17M |
| September 25, 2026 | 45.39M |
| September 24, 2026 | 48.43M |
| September 23, 2026 | 52.68M |
| September 22, 2026 | 55.72M |
| September 21, 2026 | 53.29M |
| Date | Value |
|---|---|
| September 18, 2026 | 52.08M |
| September 17, 2026 | 57.55M |
| September 16, 2026 | 57.55M |
| September 15, 2026 | 53.90M |
| September 14, 2026 | 56.94M |
| September 11, 2026 | 51.47M |
| September 10, 2026 | 52.08M |
| September 09, 2026 | 53.29M |
| September 08, 2026 | 52.08M |
| September 04, 2026 | 52.68M |
| September 03, 2026 | 53.29M |
| September 02, 2026 | 55.72M |
| September 01, 2026 | 51.47M |
| August 31, 2026 | 52.08M |
| August 28, 2026 | 53.29M |
| August 27, 2026 | 56.33M |
| August 26, 2026 | 56.94M |
| August 25, 2026 | 58.16M |
| August 24, 2026 | 54.51M |
| August 21, 2026 | 56.94M |
| August 20, 2026 | 56.33M |
| August 19, 2026 | 56.94M |
| August 18, 2026 | 55.72M |
| August 17, 2026 | 56.94M |
| August 14, 2026 | 57.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.944M |
| Total Expenses (Quarterly) | 7.944M |
| EPS Diluted (Quarterly) | -0.1307 |
| Earnings Yield | -55.11% |
| Normalized Earnings Yield | -56.47 |